Genotyping takes us closer to an osteoporosis fingerprint
For the first time ever, an extensive genome-wide search has been
undertaken to find the genes linked to osteoporosis and fracture. Five
regions of interest have been identified that appear to warrant further
scientific investigation.
From the age of 60, 40% women and 25% men will sustain a fracture due
to osteoporosis, with the risk being higher in people with a family
history of fracture. There are 30,000 genes in the human genome,
but until now few have been unequivocally linked to osteoporosis and
fragility fractures.
The Garvan Institute of Medical Research collaborated with the
Icelandic genetics company, deCode, in a project that looked at 1500
women from Garvan’s Dubbo Osteoporosis Epidemiology Study as well as
more than 12,000 women from Iceland and Denmark.
The results of this multi-nation study are reported in a paper
appearing online today in the New England Journal of
Medicine.
“Genome-wide genotyping, a very demanding and labour-intensive
procedure, measures genetic variations called ‘Snips’ (SNPs or single
nucleotide polymorphisms), within each of our 30,000 genes,” said
Garvan’s Associate Professor Tuan Nguyen, who has been involved with
the Dubbo project over a period of nearly 20 years. “The collaborative
study examined more than 300,000 such markers and found 12 that were
linked to bone mineral density and 6 linked to fragility fractures.
Some of these Snips are close to genes that are already known to be
associated with osteoporosis,”
Professor John Eisman, Head of Garvan’s Bone Program, is very pleased
with these findings. “This international study and the access to the
information it brings is a positive example of the value of world-wide
scientific collaborations in the area of human genetics. The
study identified a number of regions in the human genome that are
already known to be important in bone biology, while others are yet to
be investigated,” he said.
“The next step will be identifying what those genes are and how they
might contribute to our understanding of osteoporosis and its
prevention. This is an important example of Australian science
participating in international science at the highest level.”
The discovery of genes linked to osteoporosis will allow researchers to
better develop prognostic models, and help clinicians identify
individuals with high risk of fracture for intervention.
ABOUT GARVAN
The Garvan Institute of Medical Research was founded in 1963.
Initially a research department of St Vincent's Hospital in Sydney, it
is now one of Australia's largest medical research institutions with
approximately 400 scientists, students and support staff. Garvan’s main
research programs are: Cancer, Diabetes & Obesity, Immunology and
Inflammation, Bone, and Neuroscience. The Garvan’s mission is to make
significant contributions to medical science that will change the
directions of science and medicine and have major impacts on human
health. The outcome of Garvan’s discoveries is the development of
better methods of diagnosis, treatment, and ultimately, prevention of
disease.
All media enquiries should be directed to:
Alison Heather 02 9295 8128 or Jackie Crossman on 0402 218 662



